The 2nd Edition Immuno-Oncology & Biomarker Conference, organized by Veridon Global, will take place on 19–20 October 2026 in Philadelphia, bringing together leading experts from pharmaceutical, biotechnology, academia and healthcare organizations to explore the latest breakthroughs shaping the future of cancer treatment.
The conference will showcase the rapidly evolving landscape of Immuno-Oncology, covering next-generation immunotherapies, monoclonal and bispecific antibodies, CAR-T and other adoptive cell therapies, immune checkpoint inhibitors, tumour microenvironment research, translational oncology, and innovative combination treatment strategies. Discussions will focus on overcoming resistance mechanisms, identifying novel immune targets, and accelerating the translation of scientific discoveries into clinical success.
Alongside these advancements, the program will highlight how biomarker-driven precision medicine is transforming oncology through AI-powered analytics, multi-omics integration, liquid biopsy, minimal residual disease (MRD) monitoring, radiomics, spatial biology, and advanced companion diagnostics. Sessions will explore how predictive and prognostic biomarkers are enabling smarter patient selection, improving therapeutic outcomes, and supporting the development of targeted and personalized therapies.
With a strong emphasis on collaboration between researchers, clinicians, pharmaceutical companies, CROs, diagnostic innovators, and technology providers, the conference offers a platform to exchange scientific insights, share real-world experiences, and foster strategic partnerships that accelerate innovation across the Immuno-Oncology and biomarker ecosystem.